CompletedPhase 2

A Clinical Study of TQH2722 Injection in the Treatment of Chronic Sinusitis With or Without Nasal Polyps.

China160 participantsStarted 2023-12-28

Plain-language summary

To evaluate the effectiveness, safety and pharmacokinetics of TQH2722 injection in patients with chronic sinusitis with or without nasal polyps.

Age range18 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

✕. Forced expiratory volume in the first second (FEV1) ≤ 50% of normal estimates, or
✕. Acute exacerbation of asthma within 90 days prior to screening, requiring hospitalization (\>24 hours), or
✕. used daily doses higher than 1000 mcg of fluticasone or equivalent inhaled corticosteroids (ICS);

Changes in nasal polyp score in Part A

Timeframe: Up to 16 weeks.

Changes in sinus CT scan Lund Mackay score in Part B

Timeframe: Up to 16 weeks.

NCT IDNCT06089278

SponsorChia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2025-03-30